Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Get Free Report) shares dropped 4.4% during trading on Friday . The stock traded as low as $38.50 and last traded at $38.95. Approximately 1,112 shares changed hands during trading, a decline of 98% from the average daily volume of 48,576 shares. The stock had previously closed at $40.74.
Analyst Upgrades and Downgrades
Separately, JPMorgan Chase & Co. initiated coverage on Ascentage Pharma Group International in a research note on Thursday, March 27th. They issued an "overweight" rating for the company.
Check Out Our Latest Research Report on Ascentage Pharma Group International
Ascentage Pharma Group International Stock Performance
The stock's 50 day moving average price is $31.22. The company has a current ratio of 1.26, a quick ratio of 1.26 and a debt-to-equity ratio of 3.24.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Ascentage Pharma Group International stock. Monashee Investment Management LLC purchased a new stake in shares of Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 159,942 shares of the company's stock, valued at approximately $3,511,000. Monashee Investment Management LLC owned 0.18% of Ascentage Pharma Group International at the end of the most recent reporting period.
About Ascentage Pharma Group International
(
Get Free Report)
Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.
Further Reading
Before you consider Ascentage Pharma Group International, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascentage Pharma Group International wasn't on the list.
While Ascentage Pharma Group International currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
